Jeffrey Tangney, the chief executive officer of Doximity, Inc. (NYSE:DOCS), reported the disposition of 8,505 shares of Class A Common Stock on August 15, according to an SEC Form 4 filing. Transaction value based on SEC Form 4 weighted average sale price ($24.80). What was the impetus for this transaction?The disposition was a non-discretionary event executed to satisfy tax withholding requirements upon the vesting of previously granted equity awards and does not reflect a market-based assessment of the stock by the executive.
How significant is the CEO's remaining stake in the company?Tangney continues to hold 2,531,955 shares directly, which represents a 1% ownership interest in the company and underscores significant alignment with long-term shareholders. Did this transaction materially impact the executive's total ownership?The withholding of 8,505 shares resulted in a marginal 0.3% reduction in direct holdings, leaving the core equity position effectively intact following the underlying vesting event. Share Price (as of market close 2026-08-14) Doximity operates a cloud-hosted digital platform that provides healthcare practitioners with specialized tools for peer connectivity, patient care coordination, remote consultations, medical research access, and professional development.
The company generates revenue through subscription-based services and licensing arrangements with pharmaceutical companies and healthcare organizations that utilize the platform to engage with medical professionals. The primary customer base consists of pharmaceutical companies seeking to reach physicians and healthcare organizations seeking to optimize clinical workflows and practitioner engagement across the United States healthcare system. Doximity is a leading digital health platform serving the U.S. healthcare practitioner community with approximately 880 employees and a market capitalization of $4.6 billion.
The company has achieved substantial profitability with TTM net income of $167.0 million on revenue of $655.6 million, demonstrating strong unit economics and operational efficiency. Doximity's competitive advantage derives from its comprehensive practitioner network, integrated suite of clinical and professional tools, and established relationships with pharmaceutical and healthcare organization customers. Tangney co-founded Doximity and has been running it for over 15 years, which makes him the insider whose filings matter the most, but this one tells you close to nothing.
The shares went to taxes on vested stock; three other insiders had the same thing happen on the same day, and he still holds more than 2.5 million shares directly.The business underneath is in a stranger spot than the quarter suggests. Revenue rose 7% to $156.6 million, and management raised the full-year range in the August 6 release, but the September quarter is guided to $170 million to $171 million, roughly 1% growth at the midpoint against last year's 23% comparison. Gross margin slipped to 87.5% from 91.2% as AI compute costs climbed, adjusted EBITDA fell 6%, and net income landed at $24.3 million against $53.3 million a year ago, which is a hard fall for a quarter the company is calling a beat.
Tangney told analysts that "this is our AI investment year." The pressure point, meanwhile, is sequencing. Most of the AI search revenue already under contract isn't recognized until the fiscal third quarter, so the spending shows up well before the payoff does. And for now, the stock is under immense pressure, cratering over 60% this past year alone.
Extract — continue reading at the source.
